PFIZ34 Stock Overview
Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 3/6 |
| Past Performance | 0/6 |
| Financial Health | 1/6 |
| Dividends | 3/6 |
Pfizer Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$34.81 |
| 52 Week High | US$51.00 |
| 52 Week Low | US$31.66 |
| Beta | 0.57 |
| 1 Month Change | 2.87% |
| 3 Month Change | 2.32% |
| 1 Year Change | -27.84% |
| 3 Year Change | -33.06% |
| 5 Year Change | -13.86% |
| Change since IPO | 302.43% |
Recent News & Updates
Recent updates
Shareholder Returns
| PFIZ34 | BR Pharmaceuticals | BR Market | |
|---|---|---|---|
| 7D | 6.0% | 4.8% | 0.9% |
| 1Y | -27.8% | -13.4% | 15.2% |
Return vs Industry: PFIZ34 underperformed the BR Pharmaceuticals industry which returned -13.4% over the past year.
Return vs Market: PFIZ34 underperformed the BR Market which returned 15.2% over the past year.
Price Volatility
| PFIZ34 volatility | |
|---|---|
| PFIZ34 Average Weekly Movement | 3.7% |
| Pharmaceuticals Industry Average Movement | 6.1% |
| Market Average Movement | 4.7% |
| 10% most volatile stocks in BR Market | 9.0% |
| 10% least volatile stocks in BR Market | 2.3% |
Stable Share Price: PFIZ34 has not had significant price volatility in the past 3 months.
Volatility Over Time: PFIZ34's weekly volatility (4%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1849 | 88,000 | Albert Bourla | www.pfizer.com |
Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women’s health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands. It also provides medicines and vaccines in various therapeutic areas, such as biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Litfulo, Velsipity, and Cibinqo brands; amyloidosis, hemophilia, endocrine diseases, and sickle cell disease under the Vyndaqel family, Oxbryta, BeneFIX, Somavert, Ngenla, and Genotropin brands; sterile injectable and anti-infective medicines under the Sulperazon, Medrol, Zavicefta, Zithromax, and Panzyga brands; and biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Inlyta, Bosulif, Mektovi, Padcev, Adcetris, Talzenna, Tukysa, Elrexfio, Tivdak, Lorbrena, and Braftovi brands.
Pfizer Inc. Fundamentals Summary
| PFIZ34 fundamental statistics | |
|---|---|
| Market cap | R$798.60b |
| Earnings (TTM) | -R$1.46b |
| Revenue (TTM) | R$278.36b |
2.9x
P/S Ratio-546.8x
P/E RatioIs PFIZ34 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| PFIZ34 income statement (TTM) | |
|---|---|
| Revenue | US$54.89b |
| Cost of Revenue | US$22.28b |
| Gross Profit | US$32.61b |
| Other Expenses | US$32.90b |
| Earnings | -US$288.00m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.051 |
| Gross Margin | 59.41% |
| Net Profit Margin | -0.52% |
| Debt/Equity Ratio | 84.4% |
How did PFIZ34 perform over the long term?
See historical performance and comparisonDividends
6.0%
Current Dividend Yield-3,236%
Payout RatioDoes PFIZ34 pay a reliable dividends?
See PFIZ34 dividend history and benchmarks| Pfizer dividend dates | |
|---|---|
| Ex Dividend Date | May 09 2024 |
| Dividend Pay Date | Jun 20 2024 |
| Days until Ex dividend | 3 days |
| Days until Dividend pay date | 45 days |
Does PFIZ34 pay a reliable dividends?
See PFIZ34 dividend history and benchmarks